A group of academics is arguing that countries seeking access to a groundbreaking HIV prevention drug from Gilead Sciences ...

Lenacapavir, a once-a-year injection, can treat HIV, prevent transmission and stop new infections — all with a single shot.

PEPFAR had been set to lead the rollout of Gilead Science's lenacapavir, which has been hailed as a "miracle" of HIV ...

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

A modelling study shows the six-monthly anti-HIV jab, lenacapavir, could end Aids in SA by 2032 — but only if between two and ...

Key to 400-employee Denali's submission is the FDA allowing measurement of a type of GAG, called heparan sulfate, in ...

Before losing her job at USAID, Katomski’s research division was considering trials for lenacapavir, the 2024 “breakthrough” drug. “All of that’s just been cut off,” she says.

As Gilead Sciences prepares to launch twice-yearly lenacapavir pre-exposure prophylaxis (PrEP) later this year, the company is also developing once-yearly formulations that could make an even greater ...

ClearBridge Investments, an investment management company, released its “ClearBridge Value Strategy” first quarter 2025 ...

At a news briefing in Geneva, UNAIDS Executive Director Winnie Byanyima said that the deal would involve Trump enabling the U.S. company Gilead to produce and license its “magical” prevention drug ...

While Gilead is eliminating 149 positions at its headquarters in Foster City, Roche is letting go of 108 workers at its ...